Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes | Ye et al. Journal of Translational Medicine 2011 9 131 http www.translational-medicine.eom content 9 1 131 METHODOLOGY JOURNAL OF TRANSLATIONAL MEDICINE Open Access Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes 1 1 2 3 2 2 1.2 Qunrui Ye Maria Loisiou Bruce L Levine Megan M Suhoski James L Riley Carl H June George Coukos 1 and Daniel J Powell Jr1 2 Abstract Background Development of a standardized platform for the rapid expansion of tumor-infiltrating lymphocytes TILs with anti-tumor function from patients with limited TIL numbers or tumor tissues challenges their clinical application. Methods To facilitate adoptive immunotherapy we applied genetically-engineered K562 cell-based artificial antigen presenting cells aAPCs for the direct and rapid expansion of TILs isolated from primary cancer specimens. Results TILs outgrown in IL-2 undergo rapid CD28-independent expansion in response to aAPC stimulation that requires provision of exogenous IL-2 cytokine support. aAPCs induce numerical expansion ofTILs that is statistically similar to an established rapid expansion method at a 100-fold lower feeder cell to TIL ratio and greater than those achievable using anti-CD3 CD28 activation beads or extended IL-2 culture. aAPC-expanded TILs undergo numerical expansion of tumor antigen-specific cells remain amenable to secondary aAPC-based expansion and have low CD4 CD8 ratios and FOXP3 CD4 cell frequencies. TILs can also be expanded directly from fresh enzyme-digested tumor specimens when pulsed with aAPCs. These young TILs are tumor-reactive positively skewed in CD8 lymphocyte composition CD28 and CD27 expression and contain fewer FOXP3 T cells compared to parallel IL-2 cultures. Conclusion Genetically-enhanced aAPCs represent a standardized off-the-shelf platform for the direct ex vivo expansion ofTILs of suitable number phenotype and function for use in adoptive immunotherapy. Introduction Adoptive .